Related Experiment Videos
Dynorphin-(1-13). I. Structure-function relationships of Ala-containing analogs
International Journal of Peptide and Protein Research
|April 1, 1984
Summary
Synthesizing Dynorphin-(1-13) analogs revealed key amino acid positions influencing opiate receptor activity. Replacing specific residues, particularly Arg6 and Arg7, significantly altered peptide potency in muscle and brain assays.
Area of Science:
- Medicinal Chemistry
- Neuropharmacology
- Peptide Synthesis
Background:
- Dynorphin-(1-13) is a potent endogenous opioid peptide with diverse physiological roles.
- Understanding structure-activity relationships is crucial for developing selective opioid modulators.
Purpose of the Study:
- To synthesize and characterize Dynorphin-(1-13) analogs with single alanine substitutions.
- To evaluate the impact of these substitutions on biological activity in smooth muscle and opiate receptor binding assays.
Main Methods:
- Solid-phase peptide synthesis was employed to create Dynorphin-(1-13) analogs.
- High-performance liquid chromatography (HPLC) was used for purification.
- Relative potencies were assessed using guinea pig ileum (GPI) and mouse vas deferens (MVD) contraction assays, and [3H]-etorphine binding assays in rat brain homogenates.
Main Results:
- Alanine substitutions at positions 1 and 4 drastically reduced peptide potency (<0.2%).
- Substitutions at positions 2, 5, 6, 7, 9, and 11 also decreased activity, with Arg6 and Arg7 being particularly critical.
- Replacing Ile8 with alanine enhanced potency in MVD (191%) and binding assays (900%).
Conclusions:
- Specific amino acid residues in Dynorphin-(1-13), especially basic residues like Arg6 and Arg7, are vital for its biological activity.
- The study elucidates structure-activity relationships, identifying residues critical for opiate receptor interaction and smooth muscle effects.
- Ile8 appears to be a site for potential modification to enhance Dynorphin-(1-13) analog potency.